Tests telemedicine to adjust heart failure medicines after hospital stays
Tests telemedicine guidance for heart failure medicines in hospitalized adults, compared with usual care.
Plain-language title generated from the registry record
Registry title: Digital Solutions in Heart Therapy (DIGNITY)
Key facts
- Where
- Basel, SwitzerlandSee the site
Where in Switzerland
- University Hospital BaselBasel, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT06942221
- Record updated
- 2 December 2025
- Original description
This study aims to assess the safety and effectiveness of telemedicine guided strategy on guideline-directed medical therapy (GDMT) optimization in hospitalized patients with heart failure in comparison to usual care in Switzerland.Read full original descriptionShow less
Digital Solutions in Heart Therapy (DIGNITY) - a Randomized Controlled Trial Using Telemedicine for Heart Failure Treatment
This study aims to assess the safety and effectiveness of telemedicine guided strategy on guideline-directed medical therapy (GDMT) optimization in hospitalized patients with heart failure in comparison to usual care in Switzerland.
Inclusion: Age > 18 years at the time of hospital admission; Ability to use a (smart)phone and/or tablet for the follow-up; Documented left ventricular ejection fraction (LVEF) > 40% assessed within preceding 12 months; Not treated with optimal doses of oral HF therapies within 2 days before anticipated hospital discharge for acute HF in at least one of the medication categories (for details see Table 1 on page 10); Hospitalized due to acute HF decompensation; Specific measures within 24 hours prior to randomization; Systolic blood pressure > 100 mmHg, and heart rate > 60bpm; Serum potassium < 5mmol/L.
Exclusion: Clear intolerance to high doses of betablockers, ACE inhibitors, or ARBs; Myocardial infarction, unstable angina or cardiac surgery within 3 months, percutaneous transluminal coronary intervention within 1 months prior to screening; Cardiac resynchronization therapy device implantation within 3 months prior to screening; Participation in other clinical trials for drugs; Inability to use a (smart)phone or tablet; Estimated glomerular filtration rate <30ml/min/1.73m2 or dialysis; Presence of significant obstructive lesion of the left ventricular outflow tract; Amyloid cardiomyopathy; Pregnant or nursing women; Women of child-bearing potential who are unwilling to abstain from sexual intercourse with men or practice appropriate contraception.